Grantham Mayo Van Otterloo & Co. LLC Acquires 103,601 Shares of Haleon PLC Sponsored ADR $HLN

Grantham Mayo Van Otterloo & Co. LLC lifted its holdings in shares of Haleon PLC Sponsored ADR (NYSE:HLN) by 13.2% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 888,839 shares of the company’s stock after acquiring an additional 103,601 shares during the period. Grantham Mayo Van Otterloo & Co. LLC’s holdings in Haleon were worth $7,973,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in the business. Golden State Wealth Management LLC boosted its stake in Haleon by 107.6% during the 2nd quarter. Golden State Wealth Management LLC now owns 2,721 shares of the company’s stock valued at $28,000 after purchasing an additional 1,410 shares during the last quarter. SOA Wealth Advisors LLC. increased its holdings in Haleon by 60.5% during the 3rd quarter. SOA Wealth Advisors LLC. now owns 3,105 shares of the company’s stock worth $28,000 after purchasing an additional 1,170 shares in the last quarter. Citizens National Bank Trust Department raised its stake in shares of Haleon by 167.4% in the third quarter. Citizens National Bank Trust Department now owns 3,276 shares of the company’s stock worth $29,000 after purchasing an additional 2,051 shares during the last quarter. Atlantic Union Bankshares Corp lifted its holdings in shares of Haleon by 293.7% in the third quarter. Atlantic Union Bankshares Corp now owns 3,697 shares of the company’s stock valued at $33,000 after purchasing an additional 2,758 shares in the last quarter. Finally, Geneos Wealth Management Inc. lifted its holdings in shares of Haleon by 33.0% in the first quarter. Geneos Wealth Management Inc. now owns 4,846 shares of the company’s stock valued at $50,000 after purchasing an additional 1,203 shares in the last quarter. Institutional investors and hedge funds own 6.67% of the company’s stock.

Analyst Ratings Changes

HLN has been the subject of several recent research reports. Weiss Ratings reiterated a “hold (c)” rating on shares of Haleon in a report on Thursday, January 22nd. HSBC upgraded Haleon from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, January 21st. Jefferies Financial Group reiterated a “buy” rating on shares of Haleon in a research note on Tuesday, January 20th. Deutsche Bank Aktiengesellschaft downgraded shares of Haleon from a “hold” rating to a “sell” rating in a report on Monday, January 12th. Finally, Morgan Stanley restated an “overweight” rating on shares of Haleon in a report on Monday, December 15th. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $12.33.

Haleon Price Performance

Haleon stock opened at $10.27 on Tuesday. The business’s 50 day simple moving average is $10.50 and its 200 day simple moving average is $9.85. Haleon PLC Sponsored ADR has a 12 month low of $8.71 and a 12 month high of $11.42. The company has a market cap of $45.71 billion, a price-to-earnings ratio of 26.32 and a beta of 0.18. The company has a current ratio of 0.92, a quick ratio of 0.71 and a debt-to-equity ratio of 0.47.

Haleon Dividend Announcement

The firm also recently disclosed a dividend, which will be paid on Thursday, May 14th. Shareholders of record on Friday, April 10th will be issued a dividend of $0.1307 per share. The ex-dividend date of this dividend is Friday, April 10th. This represents a yield of 251.0%. Haleon’s dividend payout ratio is 28.21%.

Haleon Profile

Haleon plc (NYSE:HLN) is a global consumer healthcare company formed through the separation of a large pharmaceutical group’s consumer health business in 2022. Headquartered in the United Kingdom, Haleon develops, manufactures and markets a broad portfolio of over?the?counter medicines, oral health products, vitamins, minerals and supplements, and other consumer health goods designed for daily self?care and symptom relief.

The company’s product mix spans categories such as oral care (toothpastes and sensitivity treatments), pain relief and analgesics, respiratory remedies, digestive health products, topical treatments and nutritional supplements.